您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8325 处方药 7952 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 英国药房
产地国家: 英国
所属类别: 心血管系统药物->抗高血压药物
处方药:处方药
包装规格: 10毫升/注射剂 , 5 注射剂/批
计价单位:
  点击放大  
生产厂家英文名:
Baxter
该药品相关信息网址1:
https://reference.medscape.com/drug/brevibloc-esmolol-342358
该药品相关信息网址2:
http://www.baxter.com.pr/healthcare_professionals/products/brevibloc.html
原产地英文商品名:
Brevibloc Premixed 10mg/ml 100mg Solution (USD226 for order less than 5, USD178 for order more than 5)
原产地英文药品名:
Esmolol
中文参考商品译名:
Brevibloc预混合10mg/ml, 100mg 溶液 (226美元: 订单少于5,178美元: 订单超过5)
中文参考药品译名:
艾司洛尔
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative
临床试验期:
完成
中文适应病症参考翻译1:
手术期,术后或其他急需情况下心房颤动或心房扑动患者心室率的快速控制
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201883001552734.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文替Brevibloc处方资料(仅供参考)

适应症和用法

Brevibloc(艾司洛尔盐酸盐)适用于围手术期,术后或其他急需情况下心房颤动或心房扑动患者心室率的快速控制,其中需要用短效剂短期控制心室率。 Brevibloc(艾司洛尔盐酸盐)不适用于预期转移到另一种药物的慢性环境中。 Brevibloc(艾司洛尔盐酸盐)也适用于术中和术后心动过速和/或高血压。

重要风险信息

窦性心动过缓,心脏阻滞大于一度,心源性休克或明显心力衰竭的患者禁用。

在输注过程中要小心使用并仔细监测LV功能障碍,CHF,低血压,反应性气道疾病和糖尿病患者。一般而言,支气管痉挛性疾病患者不应接受β受体阻滞剂。由于相对β1的选择性和可滴定性,在患有支气管痉挛疾病的患者中可以谨慎使用艾司洛尔HCl。滴定至尽可能低的剂量。

不应用于治疗高血压,主要是由于与低温有关的血管收缩或预防心动过速和/或高血压。

最常见的副作用是低血压;无症状(25%)和症状(12%),主要是头晕和发汗。低血压通常在剂量减少或输注终止后30分钟内逆转。输液部位反应(8%)。

Indications & Usage

Brevibloc (esmolol HCl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Brevibloc (esmolol HCl) is not intended for use in chronic settings where transfer to another agent is anticipated. Brevibloc (esmolol HCl) is also indicated for intraoperative and postoperative tachycardia and/or hypertension.

Important Risk Information

Contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt cardiac failure.

Use with caution and monitor carefully during infusion for patients with LV dysfunction, CHF, hypotension, reactive airway disease, and diabetes. In general, patients with bronchospastic disease should not receive beta blockers. Due to the relative beta1 selectivity and titratability, esmolol HCl may be used with caution in patients with bronchospastic disease. Titrate to the lowest possible dose.

Should not be used for treatment of hypertension due primarily to vasoconstriction associated with hypothermia or to prevent tachycardia and/or hypertension.

The most common side effect was hypotension; asymptomatic (25%) and symptomatic (12%), mainly dizziness and diaphoresis. Hypotension usually reverses within 30 minutes of decrease of dose or termination of infusion. Infusion site reactions (8%).

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201883001552734.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

2011-4-7更新

更新日期: 2017-09-12
附件:
201883001552734.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com